RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
Status:
Completed
Trial end date:
2016-12-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if two topical formulations of CD101 are safe and
effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC)
compared to oral fluconazole.